A monoclonal antibody inhibiting LINGO-1 (opicinumab) however showed no clear improvement in phase II trials in MS [30], or in patients with their first acute optic neuritis incident though it showed improvement in visual evoked potentials [31]. This evidence concerns the gene LINGO1 and myeloid sarcoma.